| Code | CSB-RA018727MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to BAY-1158061, targeting the prolactin receptor (PRLR), a transmembrane receptor belonging to the cytokine receptor superfamily. PRLR mediates the biological effects of prolactin, a hormone critical for mammary gland development, lactation, reproduction, and immune regulation. Upon prolactin binding, PRLR activates multiple intracellular signaling pathways, including JAK2/STAT5, MAPK, and PI3K/AKT cascades. Dysregulated PRLR signaling has been implicated in various pathological conditions, particularly hormone-dependent cancers such as breast and prostate cancer, where it contributes to tumor cell proliferation, survival, and metastasis.
BAY-1158061 is an investigational therapeutic antibody developed to block PRLR signaling and has been evaluated in preclinical and clinical studies for cancer treatment. This biosimilar provides researchers with a valuable tool for investigating PRLR-mediated signaling mechanisms, exploring the role of prolactin-PRLR axis in tumorigenesis, and studying potential therapeutic interventions in endocrine-related disorders. It supports various research applications in oncology, endocrinology, and reproductive biology.
There are currently no reviews for this product.